SCHEMBL4117233

SCHEMBL4117233

CCOc1c(OC)cccc1C(=O)c1cc(Cl)ccc1-n1cccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
LMNA P02545 3/20 0.40
TSHR P16473 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
SMN1; SMN2 Q16637 2/20 0.40
TSPO P30536 1/20 0.40
RAB9A P51151 1/20 0.40
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
GAA P10253 2/20 0.39
MAPT P10636 2/20 0.39
USP2 O75604 1/20 0.39
TP53 P04637 1/20 0.39
ALOX15 P16050 1/20 0.39
MAPK1 P28482 1/20 0.39
KCNMA1 Q12791 1/20 0.39
KDM4E B2RXH2 1/20 0.39
KCNK3 O14649 1/20 0.39
KCNK9 Q9NPC2 1/20 0.39
MRGPRX4 Q96LA9 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4122687 0.91 L3MBTL1 (0.44) L3MBTL1LMNANPSR1SMN1; SMN2RAB9A
SCHEMBL4132642 0.86 FNTA (0.39) LMNATSHRNPSR1SMN1; SMN2RAB9A
SCHEMBL4133055 0.85 GAA (0.46) L3MBTL1MEN1KMT2AGAA
SCHEMBL4119261 0.85 L3MBTL1 (0.50) L3MBTL1LMNATSHRRAB9AMEN1
SCHEMBL4124299 0.84 RECQL (0.50) LMNATSHRSMN1; SMN2MEN1KMT2A
SCHEMBL4111159 0.83 L3MBTL1 (0.44) L3MBTL1LMNATSHRTSPORAB9A
SCHEMBL4118982 0.81 LMNA (0.41) L3MBTL1LMNATSHRNPSR1KDM4E
SCHEMBL4123573 0.81 NR1H4 (0.36) LMNATSHRSMN1; SMN2MEN1KMT2A
SCHEMBL4123566 0.81 NR1H4 (0.36) LMNATSHRSMN1; SMN2MEN1KMT2A
SCHEMBL4709316 0.80 GAA (0.40) L3MBTL1GAATUBB4ATUBBTUBA3C

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
US-20090181942-A1 TRICYCLIC COMPOUNDS DAIICHI SANKYO COMPANY, LIMITED (JP) 2009-07-16 US disclosed
EP-1939205-A1 TRICYCLIC COMPOUND Daiichi Sankyo Company, Limited (JP) 2008-07-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090181942-A1 TRICYCLIC COMPOUNDS FDFT1, COASY, HMGCR L3MBTL1 661/4885LMNA 1109/4885TSHR 1672/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.